88 citations
,
February 2008 in “Journal of Medicinal Chemistry”
Scientists made the first metal-based compounds from a nonsteroidalantiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.
New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
20 citations
,
March 2005 in “Current Medicinal Chemistry”
New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.
KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.
A 31-year-old who experienced severe hair loss during medical school tried various treatments, including topical and oral finasteride and minoxidil, but stopped due to side effects. They restarted treatment 10 months ago with a regimen including topical finasteride, minoxidil, retinoic acid, hydrocortisone, oral minoxidil, and light therapy, emphasizing the importance of consistency and skincare.
Pyrilutamide, a nonsteroidalantiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.